A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

The main aim of this study is to find out how well elritercept works in lowering the need for RBC transfusions. Other aims are to learn how well elritercept works in reducing the need for RBC transfusions over longer periods of time or in adults with high transfusion needs. The study will also check on how safe elritercept is and how well it is tolerated.

NCT Number	NCT06499285
Lead Sponsor	Takeda
Conditions	Myelodysplastic Syndromes
Enrollment	225 participants
Start Date	2025-05-06
Primary Completion	2028-05-01 (estimated)
Study Completion	2032-05-01 (estimated)
Updated on ClinicalTrials.gov	2026-05-13